Testing effectiveness (Phase 2)Temporarily pausedNCT06639607
What this trial is testing
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Who this might be right for
Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastoma+1 more
Washington University School of Medicine 68